RedHill reports potent inhibition of Omicron with oral COVID-19 drug candidate opaganib in vitro
TEL AVIV, Israel and RALEIGH, NC, April 11, 2022, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced study...
















